191 related articles for article (PubMed ID: 21818671)
1. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs.
Carter CT; Waters HC; Smith DB
Adv Ther; 2011 Aug; 28(8):671-83. PubMed ID: 21818671
[TBL] [Abstract][Full Text] [Related]
2. Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn's disease patients.
Kane SV; Chao J; Mulani PM
Adv Ther; 2009 Oct; 26(10):936-46. PubMed ID: 19838649
[TBL] [Abstract][Full Text] [Related]
3. Impact of persistence with infliximab on hospitalizations in ulcerative colitis.
Carter CT; Leher H; Smith P; Smith DB; Waters HC
Am J Manag Care; 2011 Jun; 17(6):385-92. PubMed ID: 21756009
[TBL] [Abstract][Full Text] [Related]
4. Healthcare costs for Crohn's disease patients treated with infliximab: a propensity weighted comparison of the effects of treatment adherence.
Feagan BG; Kozma CM; Slaton TL; Olson WH; Wan GJ
J Med Econ; 2014 Dec; 17(12):872-80. PubMed ID: 25162777
[TBL] [Abstract][Full Text] [Related]
5. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
Ollendorf DA; Lidsky L
Am J Ther; 2006; 13(6):502-6. PubMed ID: 17122530
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy.
Wan GJ; Kozma CM; Slaton TL; Olson WH; Feagan BG
J Med Econ; 2014 Jun; 17(6):384-93. PubMed ID: 24673303
[TBL] [Abstract][Full Text] [Related]
7. Effect of a continuous measure of adherence with infliximab maintenance treatment on inpatient outcomes in Crohn's disease.
Carter CT; Waters HC; Smith DB
Patient Prefer Adherence; 2012; 6():417-26. PubMed ID: 22723726
[TBL] [Abstract][Full Text] [Related]
8. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
9. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease--modelling outcomes in active luminal and fistulizing disease in adults.
Lindsay J; Punekar YS; Morris J; Chung-Faye G
Aliment Pharmacol Ther; 2008 Jul; 28(1):76-87. PubMed ID: 18410558
[TBL] [Abstract][Full Text] [Related]
10. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.
Wu EQ; Mulani PM; Yu AP; Tang J; Pollack PF
Value Health; 2008; 11(5):820-9. PubMed ID: 18489509
[TBL] [Abstract][Full Text] [Related]
11. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease.
Waters HC; Vanderpoel JE; Nejadnik B; McKenzie RS; Lunacsek OE; Lennert BJ; Goff J; Augustyn DH
J Med Econ; 2012; 15(1):45-52. PubMed ID: 22023068
[TBL] [Abstract][Full Text] [Related]
12. Infliximab use in luminal Crohn's disease.
Richter JA; Bickston SJ
Gastroenterol Clin North Am; 2006 Dec; 35(4):775-93. PubMed ID: 17129813
[TBL] [Abstract][Full Text] [Related]
13. Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia.
Offord S; Lin J; Mirski D; Wong B
Adv Ther; 2013 Mar; 30(3):286-97. PubMed ID: 23483449
[TBL] [Abstract][Full Text] [Related]
14. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.
Faught RE; Weiner JR; Guérin A; Cunnington MC; Duh MS
Epilepsia; 2009 Mar; 50(3):501-9. PubMed ID: 19183224
[TBL] [Abstract][Full Text] [Related]
15. Effects of fluticasone propionate/salmeterol combination on asthma-related health care resource utilization and costs and adherence in children and adults with asthma.
Delea TE; Hagiwara M; Stanford RH; Stempel DA
Clin Ther; 2008 Mar; 30(3):560-71. PubMed ID: 18405796
[TBL] [Abstract][Full Text] [Related]
16. Infliximab maintenance therapy is associated with decreases in direct resource use in patients with luminal or fistulizing Crohn's disease.
Taxonera C; Rodrigo L; Casellas F; Calvet X; Gómez-Camacho F; Ginard D; Castro M; Castro L; Ponce M; Martínez-Montiel P; Ricart E; Gisbert JP; López-San Román A; Morales JM; Casado MA
J Clin Gastroenterol; 2009; 43(10):950-6. PubMed ID: 19448569
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and costs of patients with persistent asthma treated with beclomethasone dipropionate hydrofluoroalkane or fluticasone propionate.
Lage MJ; Gross GN; Brewster C; Spalitto A
Adv Ther; 2009 Aug; 26(8):762-75. PubMed ID: 19669630
[TBL] [Abstract][Full Text] [Related]
18. Utilization and costs for children who have special health care needs and are enrolled in a hospital-based comprehensive primary care clinic.
Berman S; Rannie M; Moore L; Elias E; Dryer LJ; Jones MD
Pediatrics; 2005 Jun; 115(6):e637-42. PubMed ID: 15930189
[TBL] [Abstract][Full Text] [Related]
19. Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis.
Leombruno JP; Nguyen GC; Grootendorst P; Juurlink D; Einarson T
Pharmacoepidemiol Drug Saf; 2011 Aug; 20(8):838-48. PubMed ID: 21688345
[TBL] [Abstract][Full Text] [Related]
20. The cost of hospitalization in Crohn's disease.
Cohen RD; Larson LR; Roth JM; Becker RV; Mummert LL
Am J Gastroenterol; 2000 Feb; 95(2):524-30. PubMed ID: 10685762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
